

If you have
Non-Small-Cell
Lung Cancer (NSCLC)

Your Journey May Include a Different Path

Consider participating in NSCLC research

Until recently, most NSCLC was treated similarly, with therapies that destroy dividing cells regardless of whether they are cancer cells or healthy ones. Today, clinical research studies are evaluating the safety and effectiveness of investigational medicines with the goal of targeting cancer cells specifically.

Janssen is committed to transforming the way lung cancer is researched and treated. That is why we are always learning, innovating, and advancing investigational medicines with the goal of redefining what is possible in the treatment of NSCLC.

The CHRYSALIS Clinical Research Study

The CHRYSALIS clinical research study is evaluating the safety and effectiveness of one investigational medication or a combination of two investigational medications. The study includes multiple groups of people with NSCLC who have a range of different characteristics and types of cancer/subtypes. These study groups may not all be recruiting new participants at the same time.

The MET Exon 14 Skipping Group is now open for enrollment

Participants in this group need to have been diagnosed with NSCLC that has spread (metastatic) or cannot be removed by surgery (unresectable), as well as a primary gene mutation called a MET Exon 14 skipping mutation. Participants in this group will receive one investigational medication.

You may be able to take part in the CHRYSALIS Study if you:

- Are 18 years or older
- Have been diagnosed with advanced or unresectable NSCLC
- Have received prior treatment, which was not effective, or are ineligible for other currently available treatments
- Are either fully active and able to carry on all physical activities, or are restricted in strenuous activity, but can walk around and carry out light housework or office work[1]
- **For the MET Exon 14 Skipping Group:** have been diagnosed with a primary MET Exon 14 skipping mutation

Additional eligibility criteria will be assessed by the study doctor or staff.

FAQs

What's involved with participation in the CHRYSALIS Study?

Participants will receive the investigational medication or combination of medications while completing various study tests and procedures.

- The study duration will vary from person to person depending on the response to investigational medication
- Dosing will take place once a week for the first four weeks of study medication cycle 1, and then every other week for the rest of the study
- Each study medication cycle will last 28 days, depending on the group
- Participants and the study staff will know which investigational medication or medications are being given. There is no placebo in this study
- Participants may leave the study at any point in time

Does participating in this study cost anything?

All study-required visits, tests, and medications may be provided at no cost to qualified participants. The study will not pay for other medical care or current medication(s) needed to support your daily healthcare routine.

In addition, reimbursement for study-required travel, meals, and parking may be available.

If pre-qualified, what can I expect on my first visit to the study clinic?

This initial appointment is an opportunity for you to:

- **Learn more about the CHRYSALIS Study.** You'll be speaking with a study doctor at the study clinic to learn more regarding your participation in this study.
- **Ask any important questions you may have.** These can be any questions you may have about this study or clinical research in general.
- **Determine if the CHRYSALIS Study may be right for you.** After speaking with the study doctor and learning details about this study, the study staff will perform a series of screening tests to determine if you are eligible to participate. If you are eligible, you and your doctor can then decide if this study is right for you. No tests for the actual study will be given at this time. If you agree to take part, the study staff will ask you to review and sign a consent form.

What if my condition worsens or I have side effects?

You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience worsening of your disease at any time during the study, your study doctor will ask you to come to the study clinic to determine disease progression and decide upon a course of action. If your disease is progressing, you will be asked to complete an end of treatment visit 30 days after your last dose of investigational medication. You will then enter the follow-up phase with visits to the study clinic or telephone contact every 12 weeks until the end of study to find out how you are doing, if you have had any side effects, and if you have started any new cancer treatments.

Where are the study clinics located?

There are study clinics located throughout the United States. Find a location near you by visiting https://janssenoncologyclinicaltrials.com/lc/locations. To see a list of participating study clinics in over 11 countries globally, visit https://janssenoncologyclinicaltrials.com/lc/countries.

SOURCE:
[1]*ecog-acrin.org/resources/ecog-performance-status*

Janssen Research & Development, LLC
61186372EDI1001_ENG10
Version 1.0, 30April2020

CHRYSALIS

janssen